Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy
Main Author: | |
---|---|
Publication Date: | 2012 |
Other Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositório Institucional da UNIFESP |
Download full: | http://repositorio.unifesp.br/handle/11600/34915 http://dx.doi.org/10.1097/QAI.0b013e31824e4da6 |
Summary: | Background: This study evaluated a wide range of viral load (VL) thresholds to identify a cut-point that best predicts new clinical events in children on stable highly active antiretroviral therapy (HAART).Methods: Cox proportional hazards modeling was used to assess the adjusted risk for World Health Organization stage 3 or 4 clinical events (WHO events) as a function of time-varying CD4, VL, and hemoglobin values in a cohort study of Latin American children on HAART >= 6 months. Models were fit using different VL cut-points between 400 and 50,000 copies per milliliter, with model fit evaluated on the basis of the minimum Akaike information criterion value, a standard model fit statistic.Results: Models were based on 67 subjects with WHO events out of 550 subjects on study. the VL cut-points of >2600 and >32,000 copies per milliliter corresponded to the lowest Akaike information criterion values and were associated with the highest hazard ratios (2.0, P = 0.015; and 2.1, P = 0.0058, respectively) for WHO events.Conclusions: in HIV-infected Latin American children on stable HAART, 2 distinct VL thresholds (>2600 and >32,000 copies/mL) were identified for predicting children at significantly increased risk for HIV-related clinical illness, after accounting for CD4 level, hemoglobin level, and other significant factors. |
id |
UFSP_e178733cc0707ab119538124a53684e2 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/34915 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Siberry, George K.Harris, D. RobertOliveira, Ricardo HugoKrauss, Margot R.Hofer, Cristina B.Tiraboschi, Adriana AparecidaMarques, HeloisaSucci, Regina C. [UNIFESP]Abreu, ThalitaDella Negra, MarinellaMofenson, Lynne M.Hazra, RohanNISDI PLACES ProtocolEunice Kennedy Shriver Natl Inst Child Hlth & HumWestat CorpUniversidade Federal do Rio de Janeiro (UFRJ)Universidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Inst Infectol Emilio Ribas2016-01-24T14:27:16Z2016-01-24T14:27:16Z2012-06-01Jaids-Journal of Acquired Immune Deficiency Syndromes. Philadelphia: Lippincott Williams & Wilkins, v. 60, n. 2, p. 214-218, 2012.1525-4135http://repositorio.unifesp.br/handle/11600/34915http://dx.doi.org/10.1097/QAI.0b013e31824e4da610.1097/QAI.0b013e31824e4da6WOS:000304436600025Background: This study evaluated a wide range of viral load (VL) thresholds to identify a cut-point that best predicts new clinical events in children on stable highly active antiretroviral therapy (HAART).Methods: Cox proportional hazards modeling was used to assess the adjusted risk for World Health Organization stage 3 or 4 clinical events (WHO events) as a function of time-varying CD4, VL, and hemoglobin values in a cohort study of Latin American children on HAART >= 6 months. Models were fit using different VL cut-points between 400 and 50,000 copies per milliliter, with model fit evaluated on the basis of the minimum Akaike information criterion value, a standard model fit statistic.Results: Models were based on 67 subjects with WHO events out of 550 subjects on study. the VL cut-points of >2600 and >32,000 copies per milliliter corresponded to the lowest Akaike information criterion values and were associated with the highest hazard ratios (2.0, P = 0.015; and 2.1, P = 0.0058, respectively) for WHO events.Conclusions: in HIV-infected Latin American children on stable HAART, 2 distinct VL thresholds (>2600 and >32,000 copies/mL) were identified for predicting children at significantly increased risk for HIV-related clinical illness, after accounting for CD4 level, hemoglobin level, and other significant factors.National Institute of Child Health and Human Development (NICHD)Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Brach, NIH, Bethesda, MD 20892 USAWestat Corp, Rockville, MD USAUniv Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Rio de Janeiro, BrazilUniv São Paulo, Fac Med Ribeirao Preto, São Paulo, BrazilUniv São Paulo, Fac Med São Paulo, São Paulo, BrazilUniversidade Federal de São Paulo, São Paulo, BrazilInst Infectol Emilio Ribas, São Paulo, BrazilUniversidade Federal de São Paulo, EPM, São Paulo, BrazilNational Institute of Child Health and Human Development (NICHD): N01-HD-3-3345National Institute of Child Health and Human Development (NICHD): HHSN267200800001CNational Institute of Child Health and Human Development (NICHD): N01-HD-8-0001Web of Science214-218engLippincott Williams & WilkinsJaids-Journal of Acquired Immune Deficiency Syndromespediatric HIV infectionviral load monitoringviral load thresholdLatin AmericaEvaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/349152022-06-02 09:05:58.073metadata only accessoai:repositorio.unifesp.br:11600/34915Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:13:57.006730Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
title |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
spellingShingle |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy Siberry, George K. pediatric HIV infection viral load monitoring viral load threshold Latin America |
title_short |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
title_full |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
title_fullStr |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
title_full_unstemmed |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
title_sort |
Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy |
author |
Siberry, George K. |
author_facet |
Siberry, George K. Harris, D. Robert Oliveira, Ricardo Hugo Krauss, Margot R. Hofer, Cristina B. Tiraboschi, Adriana Aparecida Marques, Heloisa Succi, Regina C. [UNIFESP] Abreu, Thalita Della Negra, Marinella Mofenson, Lynne M. Hazra, Rohan NISDI PLACES Protocol |
author_role |
author |
author2 |
Harris, D. Robert Oliveira, Ricardo Hugo Krauss, Margot R. Hofer, Cristina B. Tiraboschi, Adriana Aparecida Marques, Heloisa Succi, Regina C. [UNIFESP] Abreu, Thalita Della Negra, Marinella Mofenson, Lynne M. Hazra, Rohan NISDI PLACES Protocol |
author2_role |
author author author author author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum Westat Corp Universidade Federal do Rio de Janeiro (UFRJ) Universidade de São Paulo (USP) Universidade Federal de São Paulo (UNIFESP) Inst Infectol Emilio Ribas |
dc.contributor.author.fl_str_mv |
Siberry, George K. Harris, D. Robert Oliveira, Ricardo Hugo Krauss, Margot R. Hofer, Cristina B. Tiraboschi, Adriana Aparecida Marques, Heloisa Succi, Regina C. [UNIFESP] Abreu, Thalita Della Negra, Marinella Mofenson, Lynne M. Hazra, Rohan NISDI PLACES Protocol |
dc.subject.eng.fl_str_mv |
pediatric HIV infection viral load monitoring viral load threshold Latin America |
topic |
pediatric HIV infection viral load monitoring viral load threshold Latin America |
description |
Background: This study evaluated a wide range of viral load (VL) thresholds to identify a cut-point that best predicts new clinical events in children on stable highly active antiretroviral therapy (HAART).Methods: Cox proportional hazards modeling was used to assess the adjusted risk for World Health Organization stage 3 or 4 clinical events (WHO events) as a function of time-varying CD4, VL, and hemoglobin values in a cohort study of Latin American children on HAART >= 6 months. Models were fit using different VL cut-points between 400 and 50,000 copies per milliliter, with model fit evaluated on the basis of the minimum Akaike information criterion value, a standard model fit statistic.Results: Models were based on 67 subjects with WHO events out of 550 subjects on study. the VL cut-points of >2600 and >32,000 copies per milliliter corresponded to the lowest Akaike information criterion values and were associated with the highest hazard ratios (2.0, P = 0.015; and 2.1, P = 0.0058, respectively) for WHO events.Conclusions: in HIV-infected Latin American children on stable HAART, 2 distinct VL thresholds (>2600 and >32,000 copies/mL) were identified for predicting children at significantly increased risk for HIV-related clinical illness, after accounting for CD4 level, hemoglobin level, and other significant factors. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012-06-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:27:16Z |
dc.date.available.fl_str_mv |
2016-01-24T14:27:16Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Jaids-Journal of Acquired Immune Deficiency Syndromes. Philadelphia: Lippincott Williams & Wilkins, v. 60, n. 2, p. 214-218, 2012. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/34915 http://dx.doi.org/10.1097/QAI.0b013e31824e4da6 |
dc.identifier.issn.none.fl_str_mv |
1525-4135 |
dc.identifier.doi.none.fl_str_mv |
10.1097/QAI.0b013e31824e4da6 |
dc.identifier.wos.none.fl_str_mv |
WOS:000304436600025 |
identifier_str_mv |
Jaids-Journal of Acquired Immune Deficiency Syndromes. Philadelphia: Lippincott Williams & Wilkins, v. 60, n. 2, p. 214-218, 2012. 1525-4135 10.1097/QAI.0b013e31824e4da6 WOS:000304436600025 |
url |
http://repositorio.unifesp.br/handle/11600/34915 http://dx.doi.org/10.1097/QAI.0b013e31824e4da6 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Jaids-Journal of Acquired Immune Deficiency Syndromes |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
214-218 |
dc.publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460265445031936 |